Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
TRDA compared with SKYE: revenue, margins and what each company keeps, and the suppliers and customers both name
TRDA
Entrada Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SKYE
Skye Bioscience, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
TRDA
Entrada Therapeutics, Inc.
vs
SKYE
Skye Bioscience, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
TRDA
1 of 3
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
—
▼
−10.08%
—
Q2 FY26
±56.7%
▼
−2.49%
×0.04
May 7 '26
±24.3%
▼
−57.27%
×2.36
Q1 FY26
±38.0%
▲
+6.76%
×0.18
SKYE
No earnings history for SKYE.
= implied
TRDA realized, solid
SKYE realized, hatched
One scale, both sides: full bar = 58%
× = |realized| ÷ implied
Source: market data
TRDA
Entrada Therapeutics, Inc.
Change
4.86
▲
+6.91%
· post 4.87
Mkt cap
$191.4M
Revenue
$905,000
Q3 FY26
Revenue
$25M
FY25
SKYE
Skye Bioscience, Inc.
Change
1.09
▲
+4.37%
· post 1.00
Closed
Nov 6 '26
Mkt cap
$4.4M
Revenue
—
Revenue
—
vs
Compare
Closed
Nov 6 '26
TRDA
Entrada Therapeutics, Inc.
vs
SKYE
Skye Bioscience, Inc.
4.86
▲
+6.91%
post 4.87
Price
1.09
▲
+4.37%
post 1.00
$191.4M
Mkt cap
$4.4M
Q3 FY26
$905,000
Revenue
—
FY25
$25M
Revenue
—
Change
Change
TRDA
4.86
▲
+6.91%
vs
SKYE
1.09
▲
+4.37%
Closed
Nov 6 '26